KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Current Leases for 7 consecutive years, with $45.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 8.67% year-over-year to $45.5 million, compared with a TTM value of $45.5 million through Dec 2025, up 8.67%, and an annual FY2025 reading of $45.5 million, up 8.67% over the prior year.
  • Current Leases was $45.5 million for Q4 2025 at Alnylam Pharmaceuticals, up from $44.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $46.1 million in Q2 2025 and bottomed at $38.9 million in Q1 2021.
  • Average Current Leases over 5 years is $42.2 million, with a median of $41.7 million recorded in 2024.
  • The sharpest move saw Current Leases skyrocketed 34.0% in 2021, then decreased 3.21% in 2024.
  • Year by year, Current Leases stood at $40.5 million in 2021, then grew by 3.5% to $42.0 million in 2022, then decreased by 1.09% to $41.5 million in 2023, then increased by 0.91% to $41.9 million in 2024, then increased by 8.67% to $45.5 million in 2025.
  • Business Quant data shows Current Leases for ALNY at $45.5 million in Q4 2025, $44.8 million in Q3 2025, and $46.1 million in Q2 2025.